In January 2017, Medicinrådet (The Danish Medicines Council) was established alongside a new appraisal process for the public reimbursement of new hospital drugs (NHDs) in Denmark. Medicinrådet‘s new appraisal process comprises a clinical value assessment for each NHD (with six levels of incremental clinical benefit), plus an economic value assessment. These assessments, together with subsequent price negotiations, inform Medicinrådet’s final reimbursement recommendation, which is implemented by the regional authorities/hospitals. We sought to analyse Medicinrådet’s appraisal process for NHDs and its recommendations to date, and to compare these with the equivalent recommendations of other European HTA bodies.
Authors: Simon Rothwell, Richard Macaulay
To find out more about this poster you can register to download it here after the ISPOR event.